Side Letter: China PE’s returns rethink; secondaries deal deferrals; healthcare’s hype
LPs want more bang for their buck when backing Chinese managers. Plus: Secondaries buyers are using deferrals to bridge the gulf in pricing expectations; and RiverGlade rides the healthcare wave. Here's today's brief, for our valued subscribers only.
